Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.

Registry numberNCT01167881
StatusCompleted
PhasePhase 3
SponsorBoehringer Ingelheim
Enrollment1,549 participants
DesignInterventional, Randomized, Parallel, Masking: Double
ConditionsDiabetes Mellitus, Type 2
InterventionsBI 10773; Glimepiride; Placebo; Placebo
StartAug 2010
Primary completionAug 2013
Study completionAug 2015
Results postedYes, in the registry
Registry last updatedSep 2, 2016
CollaboratorsEli Lilly and Company

Compounds on this site that cite this trial

What the registry says the trial is about

This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2 diabetes mellitus and insufficient glycaemic control.

Primary outcomes

These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.

Outcome measureTime frame
The Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment.Baseline and 104 weeks

9 secondary outcomes also registered. See the registry record for the full list.

Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 18, 2026. See the trial changes feed for what has changed recently.

Share thisFacebookXEmail